The evolution of technology and biomaterials has permitted a parallel development of renal replacement therapies in the acute, critically ill patient. From the original description of continuous arterio-venous haemofiltration, new techniques such as continuous veno-venous haemofiltration, haemodiafiltration and high flux dialysis have been developed and clinically utilised. A parallel improvement in efficiency has been achieved with urea daily clearances as high as 50 litres or more. The use of special highly permeable dialysers has also permitted to increase the clearances of larger solutes thus leading to significant removals of chemical substances involved in the acute inflammation and sepsis. In this field, recent observations have suggested to use haemofiltration with high volumes of fluid exchange. The hardware and software of the newer continuous renal replacement therapies (CRRT) are certainly the key point in achieving these results and in safely performing such challenging techniques.

Keywords:
CRRT, Acute renal failure, Dialysis efficiency, Urea clearance, Haemofiltration
This content is only available via PDF.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.